These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 32430352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy.
    Decroocq J, Marcellin L, Le Ray C, Willems L.
    Obstet Gynecol; 2014 Aug; 124(2 Pt 2 Suppl 1):481-483. PubMed ID: 25004319
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C.
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [Abstract] [Full Text] [Related]

  • 12. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct 01; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 15. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC.
    Ann Hematol; 2017 Mar 01; 96(3):507-508. PubMed ID: 27975127
    [No Abstract] [Full Text] [Related]

  • 16. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D, Soligo L, Pizzolo G, Ambrosetti A.
    Blood Transfus; 2015 Oct 01; 13(4):694-5. PubMed ID: 26057496
    [No Abstract] [Full Text] [Related]

  • 17. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS, Redner RL, Kiss JE.
    J Clin Apher; 2013 Aug 01; 28(4):321-4. PubMed ID: 23450778
    [Abstract] [Full Text] [Related]

  • 18. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia.
    Seidel MG, Urban C, Sipurzynski J, Beham-Schmid C, Lackner H, Benesch M.
    Br J Haematol; 2014 May 01; 165(3):419-21. PubMed ID: 24484542
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.